SWOG clinical trial number
EA6192

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Open
Phase
Abbreviated Title
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Research committees

Melanoma

Publication Information Expand/Collapse

2022

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192.

G Gibney;S Lee;M Atkins;T Wong;J Guerriero;T Marron;G Cohen;T-G Truong;R Carvajal;B Snyder;M Farwell;J Kirkwood;J Wolchok J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591), poster 183A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Research Committee(s)
Melanoma
Activated
07/13/2015
Open
Phase